Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Mithoowani, Hamid; Febbraro, Michela

doi:10.3390/curroncol29030150

Cited by 147 publications

(89 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment strategies for lung cancer have expanded in the past decade. However, lung cancer patients with no driver mutations or negative PD-L1 expression lack definite treatment options other than chemotherapy [ 4 ]. The discovery of a new treatable target would benefit lung cancer patients without eligible targeted agents or immunotherapies.…”

Section: Resultsmentioning

confidence: 99%

“…To cure lung cancer would be a challenging issue for today’s medicine. The treatment strategy for lung cancer includes traditional chemotherapy, radiotherapy and operation [ 3 , 4 ]. The discovery of druggable targets such as epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), MET, ROS-1receptor tyrosine kinase and Kirsten rat sarcoma viral oncogene homolog (KRAS) open avenues for treating lung cancer [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…The treatment strategy for lung cancer includes traditional chemotherapy, radiotherapy and operation [ 3 , 4 ]. The discovery of druggable targets such as epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), MET, ROS-1receptor tyrosine kinase and Kirsten rat sarcoma viral oncogene homolog (KRAS) open avenues for treating lung cancer [ 4 , 5 ]. In addition, the new strategy of boosting tumor-killing immunity via PD-1/PD-L1 and CTLA4 has advanced the treatment of lung cancer [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy

Lee

Chang

et al. 2022

JPM

View full text Add to dashboard Cite

Lung cancer is well known for its high mortality worldwide. The treatment for advanced lung cancer needs more attention to improve its survival time. A disintegrin and metallopeptidase with thrombospondin motifs 8 (ADAMTS8) has been linked to several cancer types. However, its role in lung cancer is worthy of deep investigation to promote novel drug development. This study took advantage of RNA-seq and bioinformatics to verify the role that ADAMTS8 plays in lung cancer. The functional assays suggested that ADAMTS8 mediates invasion and metastasis when expressed at a low level, contributing to poor overall survival (OS). The expression of ADAMTS8 was under the regulation of GATA Binding Protein 1 (GATA1) and executed its pathologic role through Thrombospondin Type 1 Domain Containing 1 (THSD1) and ADAMTS Like 2 (ADAMTSL2). To define the impact of ADAMTS8 in the lung cancer treatment strategy, this study further grouped lung cancer patients in the TCGA database into mutated epidermal growth factor receptor (EGFR)/wild-type EGFR and programmed death ligand 1 (PD-L1) high/low groups. Importantly, the expression of ADAMTS8 was correlated positively with the recruitment of anticancer NKT cells and negatively with the infiltration of immunosuppressive Treg and exhausted T cells. The results indicated that lung cancer patients with higher ADAMTS8 levels among wild-type EGFR or low PD-L1 groups survive longer than those with lower levels do. This study indicates that ADAMTS8 might be a treatment option for patients with lung adenocarcinoma who lack efficient targeted or immunotherapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy

Lee

Chang

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Although the incidence of lung cancer is decreasing in developed countries, it is rising in less developed parts of the world (South America, Africa, China and Eastern Europe) probably due to less rigorous smoking regulations (2). Smoking cessation, in fact, is crucial for preventing lung cancer, and public health actions aimed at quitting smoking have effectively helped to reduce the incidence of lung cancer (3)(4)(5). In addition, after receiving a lung cancer diagnosis, smoking cessation is significantly related to better overall survival, decreased post-operative complications, enhanced response to systemic therapies, better response to radiation therapy and-above all-significantly improved quality of life (6).…”

Section: Rationale/backgroundmentioning

confidence: 99%

State of the art and new perspectives in surgical treatment of lung cancer: a narrative review

Petrella¹,

Rizzo²,

Casiraghi³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background and Objective: Lung cancer is the leading cause of cancer-related deaths worldwide, and its incidence has increased over the past two decades. The standard care for stage I, stage II, and selected cases of stage IIIA non-small cell lung cancer (NSCLC) is surgical resection; in some cases, patients may be offered adjuvant systemic therapy after surgical resection. Patients with lung cancer presenting with distant metastases belong to stage IV: in this setting, some carefully selected patients may benefit from surgery within a multimodality approach.Methods: We performed a comprehensive, non-systematic review of the latest literature to define the present role of surgery in lung cancer treatment.

show abstract

“…For NSCLC patients, benefit of postoperative adjuvant platinum drug-based chemotherapy varies from a 3% decrease in the risk of death in high-risk stage IB patients to a 13% increase in benefits for stage IIIA disease, still with a higher risk of metastatic disease relapse. However, the adjuvant radiation therapy is shown to be harmful for NSCLC stage IB and II disease due to increased radiation-induced mortality risk and is less likely to provide modest benefit in stage IIIA [ 14 , 15 ]. Similarly, a combination of chemoradiation for inoperable limited stage SCLC and platinum-based chemotherapy followed by thoracic and cranial irradiation in extensive stage SCLC also suffers from relapse-refractory progression.…”

Section: Introductionmentioning

confidence: 99%

Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment

Achi

Sarbadhikary

George

et al. 2022

Cells

View full text Add to dashboard Cite

Despite therapeutic advancements, lung cancer remains the principal cause of cancer mortality in a global scenario. The increased incidence of tumor reoccurrence and progression and the highly metastatic nature of lung cancer are of great concern and hence require the investigation of novel therapies and/or medications. Naturally occurring compounds from plants serve as important resources for novel drugs for cancer therapy. Amongst these phytochemicals, Berberine, an alkaloid, has been extensively explored as a potential natural anticancer therapeutic agent. Several studies have shown the effectiveness of Berberine in inhibiting cancer growth and progression mediated via several different mechanisms, which include cell cycle arrest, inducing cell death by apoptosis and autophagy, inhibiting cell proliferation and invasion, as well as regulating the expression of microRNA, telomerase activity, and the tumor microenvironment, which usually varies for different cancer types. In this review, we aim to provide a better understanding of molecular insights of Berberine and its various derivative-induced antiproliferative and antimetastatic effects against lung cancer. In conclusion, the Berberine imparts its anticancer efficacy against lung cancers via modulation of several signaling pathways involved in cancer cell viability and proliferation, as well as migration, invasion, and metastasis.

show abstract

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Cited by 147 publications

References 70 publications

The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy

The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy

State of the art and new perspectives in surgical treatment of lung cancer: a narrative review

Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment

Contact Info

Product

Resources

About